July 22 (Reuters) – Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about $1.5 billion, to expand the drugmaking equipment provider’s presence in the fast-growing cell therapy market.
BioLife shareholders will receive $11.25 in cash and 0.1442 shares of Repligen for each share, valuing the cell-and-gene-therapy maker at $31 per share — a premium of about 6.2% to BioLife’s last close.
The boards of both companies have unanimously approved the deal, which is expected to close in the fourth quarter of 2026, pending regulatory and shareholder approvals.
(Reporting by Sahil Pandey in Bengaluru; Editing by Tasim Zahid and Sahal Muhammed)
